Industry: Pharmaceuticals & chemicals

Two deals could bring NPE risk but others stem from bankruptcies, buying and selling of business units and company product collaborations

05 July 2024

Antitrust challenges against pharma patent strategies continue to escalate

02 July 2024

Appellate court hands down guidance on induced infringement cases

28 June 2024

Alexion Pharmaceuticals denied PI requests against biosimilar eculizumab producers Amgen and Samsung Bioepis

27 June 2024

Each speciality comes with its own challenges and risks which shape how deals are negotiated and structured – and there is no ‘one-size fits all’ approach

26 June 2024

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2024

The South African pharmaceutical industry has grown substantially in recent years, while patent legislation has undergone significant divergence. Effective enforcement, prosecution and launch-to-market strategies require a keen understanding of the country’s IP and regulatory frameworks. 

24 June 2024

Regeneron’s PI against Samsung Bioepis in ongoing aflibercept litigation follows several failed attempts to obtain interim bans by biologic patentees

18 June 2024

Advice for biotech-pharma innovators to manage IP strategy while taking the risky gamble of introducing new drugs or medical devices to market

14 June 2024

AST reports that deal numbers were influenced by economic conditions, trends in litigation funding, licensing cycles, and operating companies selling non-core assets

04 June 2024

The German company remains involved in more than 70 proceedings across 20-plus European countries

28 May 2024